**Core Concept**
Aplastic anemia is a rare, potentially life-threatening failure of the bone marrow to produce new blood cells, including red blood cells, white blood cells, and platelets. The treatment of choice aims to stimulate the bone marrow to produce blood cells, reduce the risk of complications, and improve survival.

**Why the Correct Answer is Right**
The treatment of choice for aplastic anemia is immunosuppressive therapy with antithymocyte globulin (ATG) and cyclosporine. ATG works by depleting the patient's T cells, which are thought to play a role in the bone marrow failure. Cyclosporine is a calcineurin inhibitor that suppresses the activity of T cells, thereby reducing the immune system's attack on the bone marrow. This combination of immunosuppressive therapy has been shown to significantly improve the chances of successful bone marrow recovery and improve survival in patients with aplastic anemia.

**Why Each Wrong Option is Incorrect**
**Option A:** Bone marrow transplantation may be considered for some patients with aplastic anemia, but it is not the treatment of choice due to the risks associated with the procedure.
**Option B:** Androgens, such as oxymetholone, may be used to stimulate bone marrow production in some patients, but they are not the treatment of choice for aplastic anemia.
**Option D:** Supportive care, including blood transfusions and antibiotics, may be necessary for patients with aplastic anemia, but it is not the treatment of choice.

**Clinical Pearl / High-Yield Fact**
Immunosuppressive therapy with ATG and cyclosporine is the treatment of choice for aplastic anemia due to its ability to stimulate bone marrow recovery and improve survival.

**Correct Answer:** C.